Innovative Approach Boosts Immunotherapy Effectiveness in Bladder Cancer and Other Tumors

A groundbreaking discovery has paved the way for enhancing immunotherapy treatments for bladder cancer and potentially other solid tumors. The study, led by Senior Scientist Maziar Divangahi at McGill University, reveals that combining Bacillus Calmette-Guérin (BCG) therapy—used for non-muscle invasive bladder cancer—with a natural fungal molecule called β-glucan significantly improves treatment outcomes. BCG therapy, introduced over 50 years ago, involves instilling a weakened tuberculosis bacteria strain into the bladder to stimulate an immune response against cancer cells. Despite being the standard treatment, it faces limitations, such as high recurrence rates, side effects, and limited efficacy in some patients.

The innovative approach discovered by Dr. Leonardo Jurado and colleagues shows that β-glucan reinforces the body's innate immune response. It trains neutrophils, a type of immune cell derived from stem cells in the bone marrow, to aggressively combat tumor cells. This dual therapy not only enhances immune cell activation but also results in complete tumor eradication and 100% survival in preclinical mouse models of bladder cancer. Remarkably, this success suggests the potential for longer-lasting and more effective treatments, reducing recurrence and side effects.

Furthermore, this strategy might be applicable beyond bladder cancer, showing promise against other cancers like melanoma. Professor Divangahi emphasizes that training innate immune cells could revolutionize next-generation cancer immunotherapies. The research team is now preparing for clinical trials to evaluate the safety and efficacy of this combined treatment in patients.

This discovery highlights a significant step forward in personalized cancer treatment, leveraging natural immune mechanisms to achieve durable responses. It underscores Canada's leadership in cancer immunotherapy innovation and could have a profound impact globally in cancer care.